Recent Updates
Recently added Catalysts

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

ZEPPFDA catalysts, PDUFA dates & pipeline intelligence
$2.52
▼ -0.08 · -3.08%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ZEPP financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.1552W HIGH $32.85
Volume
49.40 K
Value Traded
128.65 K
Short % Float
3.93%
Days to Cover
3.9
+0.4%Week
-9.03%1 Month
-52.99%3 Month
-72%6 Month

Cash Data

Unlock ZEPP cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
36.99 M
EPS (TTM)
-2.52
P/E Ratio
-
Ent. Value
302.74 M
Total Shares
14.68 M
Float Shares
8.47 M
Insiders
0.03%
Institutions
21.86%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every ZEPP catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ZEPP Catalyst Timeline

Dated clinical, regulatory and corporate events for Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Unlock the full ZEPP catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ZEPP actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all ZEPP historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Zepp Health Corporation is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every ZEPP program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every ZEPP trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ZEPP insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Yu PengtaoOfficer (Chief Industrial Designer)Sell -4,251 98,491 held$4.09 09/24/2026
Unlock the full ZEPP insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in ZEPP for Q3 2026.
Unlock every fund holding ZEPP
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ZEPP
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ZEPP ownership
Insider and institutional ownership, quarter by quarter.

ZEPP Short Interest

Shares sold short, counted twice a month.

3.93%
Short % of Float
of tradable shares sold short
332.6K
Shares Sold Short
-0.6% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
86.0K
Avg Daily Volume
the average used for days to cover
Unlock ZEPP short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ZEPP option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ZEPP option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ZEPP options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ZEPP ranks across every disease it competes in

Competitive Position is a premium feature
See how ZEPP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ZEPP News

-ZEPP
Nov 10, 2026
ZEPPGeneral

Zepp Health Corporation to Report Third Quarter 2026 Financial Results on November 22, 2026

Zepp Health Corporation will report its third quarter 2026 financial results on November 22, 2026. A conference call is scheduled for 8:30 p.m. ET on the same day. The company, known for its Amazfit brand, has a strong global presence with over 200 million devices shipped.

Read more →
-ZEPP
Sep 2, 2026
ZEPPGeneral
▲ +8%on this news

Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for Q2 2026, showing a revenue increase of 6.9% year-over-year to US$63.5 million. Despite the revenue growth, the company experienced a net loss of US$11.3 million, up from US$7.7 million in the previous year, due to foreign-exchange impacts and increased investments in R&D and marketing. The gross margin improved to 37.4%, reflecting a favorable product mix, although challenges remain with supply constraints and rising component costs.

Read more →
-ZEPP
Aug 19, 2026
ZEPPConferences/Events

Zepp Health Corporation to Report Second Quarter 2026 Financial Results on September 1, 2026

Zepp Health Corporation will report its second quarter 2026 financial results on September 1, 2026. A conference call is scheduled for 9:30 p.m. ET, where management will discuss the results. The call will be accessible via phone and a live webcast. Zepp Health is recognized for its innovative health technology products.

Read more →
-ZEPP
Jun 18, 2026
ZEPPGeneral
▼ -7.1%on this newsshared move

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training

Amazfit has introduced the Helio Strap Pro, designed for body-worn movement intelligence in HYROX and hybrid training. However, the article provides minimal details about the product's features or benefits, leaving readers with questions about its market implications.

Read more →
-ZEPP
Jun 9, 2026
ZEPPGeneral
▼ -28.6%on this news

Zepp Health Corporation Reports First Quarter of 2026 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for Q1 2026, showing a revenue increase of 33.8% year-over-year to $51.5 million. The company launched several new products aimed at enhancing user engagement and performance. Despite a seasonal dip in consumer electronics, management expects continued growth in the upcoming quarter, with projected revenues between $63 million and $68 million.

Read more →
-ZEPP
May 26, 2026
ZEPPConferences/Events

Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026

Zepp Health Corporation will report its first quarter 2026 financial results on June 8, 2026. A conference call is scheduled for 9:30 p.m. ET on the same day, allowing stakeholders to access the results and insights. The company continues to lead in the smart wearables market, emphasizing its commitment to health technology.

Read more →
-ZEPP
Apr 24, 2026
ZEPPGeneral

Zepp Health Corporation Files 2025 Annual Report on Form 20-F

Zepp Health Corporation has filed its annual report on Form 20-F for the year ending December 31, 2025. The report is accessible on the company's investor relations website and the SEC's website. Zepp Health, known for its smart wearables, has successfully shipped over 200 million units globally.

Read more →
-ZEPP
Mar 16, 2026
ZEPPGeneral
▼ -22.1%on this news· ran to -33% by day 3

Zepp Health Corporation Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results

Zepp Health Corporation announced its fourth quarter and full year 2025 financial results, highlighting a strong revenue growth of 43% in Q4 reaching US$85.2 million. The gross margin improved to a record high of 40.4%, attributed to a more favorable product mix. Despite an adjusted operating loss of US$2.7 million, the company is optimistic about sustained growth into 2026, supported by strong sales during the holiday seasons and ongoing improvements in capital structure and inventory management.

Read more →
-ZEPP
Nov 5, 2025
ZEPPGeneral
▼ -6%on this news· ran to -40% by day 3

Zepp Health Corporation Reports Third Quarter 2025 Unaudited Financial Results

Zepp Health Corporation reported strong financial results for Q3 2025, with revenues reaching $75.8 million, a 78.5% increase year-over-year. The company achieved breakeven in adjusted operating income and improved gross margins to 38.2%. Key drivers included the successful launch of new products, notably the Amazfit T-Rex 3 Pro. However, the company also faced challenges such as supply constraints and a delay in sales due to a natural disaster.

Read more →
-ZEPP
Aug 3, 2025
ZEPPGeneral
▲ +34%on this news· ran to +87% by day 3

Zepp Health Corporation Reports Second Quarter 2025 Unaudited Financial Results

Zepp Health Corporation reported its second quarter 2025 unaudited financial results, highlighting a 46.2% year-over-year revenue growth primarily driven by Amazfit products. This marks the company's first overall revenue growth since 2021 and reflects successful strategic initiatives. The company expects continued strength in sales for the third quarter, with projections of US$72.0 million to US$76.0 million in revenue. Despite some decline in gross margin and ongoing adjusted operating losses, the firm remains optimistic about future growth stemming from its innovative product pipeline and effective marketing strategies.

Read more →
-ZEPP
May 19, 2025
ZEPPGeneral

Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for the first quarter of 2025, showcasing a 10% year-over-year revenue growth from Amazfit products. Key drivers included the successful launches of new smartwatch models, despite challenges such as net losses and fixed expenses not being fully absorbed during the low sales season. The company highlighted improvements in gross margins and is optimistic about continued sales growth for upcoming product launches, alongside significant adjustments in supply chain strategy. However, there are ongoing supply constraints affecting certain product versions.

Read more →
-ZEPP
Mar 26, 2025
ZEPPGeneral
▼ -6.8%on this news

Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for the fourth quarter and full year of 2024, indicating robust growth in revenue and gross margin despite prior year declines. The company achieved a 40.2% increase in Q4 revenue compared to the previous quarter, largely driven by the successful launch of the T-Rex 3 smartwatch. However, year-over-year comparisons showed a revenue drop of 28.3%, attributed to different product launch timing and macro headwinds. Zepp's cash position remains strong, with $111 million reported, suggesting potential for future investments.

Read more →
-ZEPP
Nov 18, 2024
ZEPPGeneral

Zepp Health Corporation Reports Third Quarter 2024 Unaudited Financial Results

Zepp Health Corporation announced its unaudited financial results for the third quarter of 2024, reporting revenues of $42.5 million, a decrease of 48.9% from the previous year. Despite a net loss of $13.3 million, the company experienced a positive trend with a 10% increase in Amazfit branded sales and achieved the highest gross margin in its history. Key product launches, particularly the T-Rex3 smartwatch, have been well-received, and the company is optimistic about sustained growth moving forward with a strong product pipeline and strategic direction.

Read more →
-ZEPP
Oct 2, 2024
ZEPPGeneral

Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion

Zepp Health Corporation announced that it has regained compliance with the NYSE's minimum price continued listing criterion, following an earlier notification that its share price had fallen below compliance standards. The NYSE communicated this positive change in a letter dated October 2, 2024. This development marks a recovery for the company after it was previously below the compliance threshold due to a low average closing price of its American depositary shares over a consecutive trading period. Zepp Health continues to operate as a prominent player in the smart wearables and health technology market.

Read more →
-ZEPP
Sep 6, 2024
ZEPPGeneral

Zepp Health Corporation Announces Plan to Implement ADS Ratio Change

Zepp Health Corporation has announced a change in the ratio of its American depositary shares (ADSs) to Class A ordinary shares. The new ratio will increase from 1 ADS representing 4 shares to 1 ADS representing 16 shares, effectively initiating a one-for-four reverse ADS split. The change is set to take effect around September 16, 2024, subject to SEC approval. The company emphasizes that this adjustment will not affect the underlying ordinary shares, although it introduces complexities regarding fractional ADSs.

Read more →
-ZEPP
Sep 3, 2024
ZEPPGeneral

Zepp Health Corporation Announces Board Changes

Zepp Health Corporation has announced new appointments to its board of directors, effective September 1, 2024. Mr. Alain Lam, Mr. Mike Yan Yeung, and Mr. Meihui Fan join the board, bringing extensive experience in finance, operations, and technology. Resigning directors include Mr. De Liu, Ms. Yunfen Lu, and Mr. Xiaojun Zhang, with some continuing their roles in the company. The new appointments are expected to strengthen the company's leadership as it navigates the health technology sector.

Read more →
-ZEPP
Aug 21, 2024
ZEPPGeneral
▲ +23%on this news

Zepp Health Corporation Reports Second Quarter 2024 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for the second quarter of 2024, revealing revenues of $40.6 million and a net loss per share of $0.04. Although revenue saw a significant decrease from the same quarter last year, the company highlighted a sequential increase in self-branded product sales and achieved a historic high in gross margin. CEO Wang Wayne Huang expressed confidence in the company's transformation phase, noting the upcoming launch of new products and strategic marketing initiatives. However, the overall decline in revenue and units shipped underscores ongoing challenges for the company.

Read more →
-ZEPP
May 20, 2024
ZEPPGeneral
▲ +5%on this news

Zepp Health Corporation Reports First Quarter 2024 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for Q1 2024, posting revenues of US$39.8 million and a net loss of US$14.6 million. The company's gross margin reached a record high of 36.8%, driven by strong sales of self-branded products, which accounted for over 85% of total revenues. Despite these positive outcomes, the firm experienced significant declines in revenue and units shipped, attributed to a lack of new product launches and overall market conditions. The company remains committed to innovation and strategic investments to improve market presence moving forward.

Read more →
-ZEPP
Mar 18, 2024
ZEPPGeneral

Zepp Health Corporation Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results

Zepp Health Corporation reported its unaudited financial results for the fourth quarter and full year of 2023, revealing a revenue of US$84.5 million, a decrease of 44% from the previous year. The company achieved a net loss of US$1.2 million but noted an all-time high gross margin of 34.7%. CEO Wayne Huang emphasized progress in strategic transformation and recent product launches, including the Amazfit Active series and Amazfit Helio Ring. Despite challenges, Zepp is focused on long-term competitiveness and innovation in the wearable technology sector.

Read more →
-ZEPP
Nov 20, 2023
ZEPPGeneral
▲ +9.8%on this news

Zepp Health Corporation Reports Third Quarter 2023 Unaudited Financial Results Amsterdam, the Netherlands

Zepp Health Corporation reported its third quarter 2023 unaudited financial results, highlighting a return to profitability with a net income of RMB3.0 million after a series of losses. Despite a significant year-over-year revenue decline of 50.1%, the company noted strong performance in its self-branded products, which contributed to the majority of revenue. The gross margin also reached a new high at 33.9%, demonstrating improved operational efficiency and successful product strategies. The company plans to leverage its technology and continue refining its product offerings to support future growth.

Read more →

About Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

763 employees zepp.com
BIOPHARMAWATCH ELITE
Trade the next ZEPP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime